Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin [GO]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse who are unable to receive additional anthracyclines, or in 2nd relapse.
Inclusion Criteria
- No history of congestive heart failure in need of medical treatment
- Creatinine clearance or radioisotope glomerular filtration rate (GFR) ≥ 60ml/min/1.73 m^2, or
- Adequate Renal Function defined as:
- ≥ 84 days since allogeneic (non-autologous) bone marrow or stem cell transplant (with or without total body irradiation [TBI]) or boost infusion (any stem cell product; not including donor lymphocyte infusion [DLI]);
- Hematopoietic growth factors: ≥ 14 days after the last dose of a long-acting growth factor (e.g., pegfilgrastim) or ≥7 days for short-acting growth factor before start of protocol treatment.
- Cytotoxic chemotherapy: Must not have received cytotoxic chemotherapy within 14 days prior to start of protocol treatment, except for corticosteroids, low dose cytarabine or hydroxyurea that can be given up to 24 hours prior to start of protocol treatment.
- Participants must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to start of protocol treatment:
- Participant, parent or guardian must sign and date informed consent and pediatric assent (when required), prior to the initiation of screening or study specific procedures, according to local law and legislation.
- Radiation therapy (RT) (before start of protocol treatment):
- Children, adolescents, and young adults with AML without demonstrated FLT3/internal tandem duplication (ITD) mutation. Ideally, the status of the mutation needs to be proven in the current relapse. Nevertheless, patients with previous FLT3/ITD negative test from prior lines can be included based on local results in order to not delay the start of treatment.
- Cellular Therapy: ≥ 42 days after the completion of donor lymphocyte infusion (DLI) or any type of cellular therapy (e.g., modified T cells, natural killer [NK] cells, dendritic cells, etc.) before start of protocol treatment.
- Participants must have enrolled on APAL2020SC, NCT Number: NCT04726241 prior to enrollment on ITCC-101/APAL2020D. (This is only applicable for participants in USA/Canada/Australia/New Zealand sites/Blood Cancer United territory).
- ≥ 42 days must have elapsed if other substantial bone marrow (BM) radiation.
- Normal serum creatinine based on age/sex
- Stem Cell Infusions (before start of protocol treatment):
- Participants must be >28 days of age and < 22 years of age at enrollment.
- Adequate Liver Function defined as:
- Participants with prior exposure to venetoclax are eligible in this trial.
- ≥ 84 days must have elapsed if prior craniospinal RT or if ≥ 50% radiation of pelvis;
- Participants must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2 (≥ 50% Lansky or Karnofsky score).
- Alkaline phosphatase ≤ 2.5 x ULN, and
- Antibodies: ≥ 21 days must have elapsed from infusion of last dose of an antibody-drug conjugate before start of protocol treatment. For unmodified antibodies or T cell engaging antibodies, 2 half-lives must have elapsed before start of protocol treatment. Any toxicity related to prior antibody therapy must be recovered to Grade ≤ 1.
- Serum glutamic pyruvic transaminase (SGPT) alanine aminotransferase (ALT) ≤ 2.5 x ULN. If higher transaminases outside these ranges (up to 5x ULN) are due to a radiographically identifiable leukemia infiltrate, the participant will remain eligible. Transaminase elevation up to 5x ULN is also allowed in case of steatosis on echography.
- Cardiac performance: Minimum cardiac function defined as:
- Adequate organ function:
- Interleukins, Interferons and Cytokines (other than Hematopoietic Growth Factors): ≥ 21 days after the completion of interleukins, interferon or cytokines (other than Hematopoietic Growth Factors) before start of protocol treatment.
- And participants must have AML which is either:
- Intrathecal cytotoxic therapy: No wash-out time is required for participants having received any combination of intrathecal cytarabine, methotrexate, and/or hydrocortisone.
- No pre-treatment diminished left ventricular function on echocardiography (shortening fraction [SF] < 25% or ejection fraction [EF] < 40%)
- Participants must have one of the following:
- Participants who are receiving cyclosporine, tacrolimus or other agents to treat or prevent either graft-versus-host disease post bone marrow transplant or organ rejection post-transplant are not eligible for this trial. Participants must be off medications to treat or prevent either graft-versus-host disease post bone marrow transplant or organ rejection post-transplant for at least 14 days prior to enrollment.
- No evidence of active graft versus host disease (GVHD).
- Untreated second relapse, in participants who are sufficiently fit to undergo another round of intensive chemotherapy, or
- No signs of congestive heart failure at presentation of relapse.
- Direct bilirubin < 1.5 x upper limit of normal (ULN), and
- ≥ 14 days have elapsed for local palliative RT (small port);
- Untreated first relapse, in participants who cannot tolerate additional anthracycline containing chemotherapy per investigator discretion.
Exclusion Criteria
- Participants who have hypersensitivity to the active substance or to any of the excipients listed in summary of product characteristics (SPC).
- Pregnancy or Breast-Feeding:
- Participants with malabsorption syndrome or any other condition that precludes enteral administration of venetoclax.
- to participants with history of veno-occlusive disease (VOD)/Sinusoidal obstruction syndrome (SOS) grade 3 or 4
- Participants who are pregnant or breast-feeding.
- Participants who have received strong and moderate CYP3A inducers such as rifampin, carbamazepine, phenytoin, and St. John's wort within 7 days of the start of study treatment.
- Participants with Down syndrome.
- Participants who in the opinion of the investigator may not be able to comply with the study requirements of the study, are not eligible.
- Concomitant Medications
- Participants with known prior allergy to any of the medications used in protocol therapy.
- Participants with isolated CNS3 disease or symptomatic CNS3 disease.
- Participants with documented active, uncontrolled infection at the time of study entry.
- Participants with Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known congenital bone marrow failure syndrome.
- Male participants must use a condom during intercourse and agree not to father a child or donate sperm during therapy and for the duration of study therapy and at least 30 days after last dose of venetoclax or 4 months after last dose of gemtuzumab ozogamicin, 6 months from the last dose of cytarabine, or 90-days after last exposure to any other chemotherapy, whichever is longer. Additional criteria to receive a gemtuzumab ozogamicin infusion: Gemtuzumab ozogamicin should not be given:
- Known hepatitis C virus (HCV), hepatitis B virus (HBV) (known positive hepatitis B virus (HBV) surface antigen (HBsAg) results), or human immunodeficiency virus (HIV) infection.
- Participants with Acute promyelocytic leukemia (APL) or Juvenile myelomonocytic leukemia (JMML).
- Participants who have consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or starfruit within 3 days of the start of study treatment.
- to participants with CD33 negative leukemic blasts (determined at local lab) Note that these participants are eligible for the study but will not be treated with gemtuzumab ozogamicin.
- Participants who are currently receiving an investigational drug other than those specified for this study.
- Participants of reproductive potential may not participate unless they have agreed to use a highly effective contraceptive method per Clinical Trial Facilitation Group (CTFG) guidelines for the duration of study therapy and at least 30 days after last dose of venetoclax, or 7 months after gemtuzumab ozogamicin treatment, or for 6 months after the completion of all study therapy, whichever is longer.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT05183035.
Locations matching your search criteria
United States
California
San Francisco
Colorado
Aurora
Connecticut
New Haven
Trumbull
Florida
Gainesville
Georgia
Atlanta
Illinois
Chicago
Indiana
Indianapolis
Iowa
Iowa City
Massachusetts
Boston
Michigan
Ann Arbor
Minnesota
Minneapolis
Missouri
Kansas City
New Jersey
Hackensack
New York
Bronx
New York
Oregon
Portland
Pennsylvania
Philadelphia
Tennessee
Memphis
Nashville
Texas
Dallas
Houston
Utah
Salt Lake City
Washington
Seattle
Relapse of AML is driven by chemotherapy resistant stem cells. One mechanism of
chemotherapeutic resistance in AML is the overexpression of the protein B-cell lymphoma 2
(BCL-2), an anti-apoptotic protein which sequesters intracellular activators of
apoptosis. Venetoclax is a selective, potent, orally bioavailable, small molecule
inhibitor of BCL-2 that restores programmed cell death in cancer cells.
This is a trial for children, adolescents and young adults with 2nd relapsed AML or 1st
relapsed AML unable to receive additional anthracycline.
This is randomized trial of venetoclax in combination with intensive chemotherapy
(fludarabine/cytarabine/gemtuzumab ozogamicin) for the first two cycles (42-day-cycles)
that would inform and evaluate if this agent is an effective option for this population
to improve its poor prognosis. Participants can receive up to two cycles of induction
chemotherapy before hematopoietic stem cell transplantation (HSCT). If participants who
have perceived clinical benefit cannot be transplanted after the 2 cycles, maintenance
treatment may be given at the discretion of the investigator. In Arm B (experimental
arm), participants can continue venetoclax if they have perceived clinical benefit, and
maintenance therapy will combine venetoclax with azacitidine for a maximum of 24 cycles.
In Arm A (control arm), participants will receive azacitidine in monotherapy. Maintenance
is continued until clinical progression or unacceptable toxicity with a maximum of 24
cycles.
Trial PhasePhase III
Trial Typetreatment
Lead OrganizationPedAL BCU, LLC
- Primary IDITCC-101/APAL2020D
- Secondary IDsNCI-2022-07200, 2021-003212-11, 2023, 2023-510160-12-00
- ClinicalTrials.gov IDNCT05183035